Merck to Buy Terns for $6.7B to Grow in Blood Cancers

Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion to obtain a promising new leukemia treatment as Merck faces patent expiration on its bestselling cancer drug. The deal bolsters Merck's oncology pipeline and helps mitigate revenue risk from the upcoming patent cliff. Expect the transaction to be sector-positive for large-cap pharma and materially affect Merck's growth outlook, though it is unlikely to move broader markets.

Analysis

Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion to obtain a promising new leukemia treatment as Merck faces patent expiration on its bestselling cancer drug. The deal bolsters Merck's oncology pipeline and helps mitigate revenue risk from the upcoming patent cliff. Expect the transaction to be sector-positive for large-cap pharma and materially affect Merck's growth outlook, though it is unlikely to move broader markets.